ImmunoPrecise Antibodies announced that its subsidiary, BioStrand has launched an advanced Retrieval Augmented Generation-based Large Language Model platform. This breakthrough platform seamlessly integrates with the company’s patented HYFT technology and LENSai platform, and the company reports that it is designed for unprecedented accuracy, interpretability and data-centric design in generative AI tools.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IPA:
